Correlation Between Apellis Pharmaceuticals and Crispr Therapeutics
Can any of the company-specific risk be diversified away by investing in both Apellis Pharmaceuticals and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Apellis Pharmaceuticals and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Apellis Pharmaceuticals and Crispr Therapeutics AG, you can compare the effects of market volatilities on Apellis Pharmaceuticals and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Apellis Pharmaceuticals with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Apellis Pharmaceuticals and Crispr Therapeutics.
Diversification Opportunities for Apellis Pharmaceuticals and Crispr Therapeutics
-0.16 | Correlation Coefficient |
Good diversification
The 3 months correlation between Apellis and Crispr is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding Apellis Pharmaceuticals and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Apellis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Apellis Pharmaceuticals are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Apellis Pharmaceuticals i.e., Apellis Pharmaceuticals and Crispr Therapeutics go up and down completely randomly.
Pair Corralation between Apellis Pharmaceuticals and Crispr Therapeutics
Given the investment horizon of 90 days Apellis Pharmaceuticals is expected to generate 1.13 times more return on investment than Crispr Therapeutics. However, Apellis Pharmaceuticals is 1.13 times more volatile than Crispr Therapeutics AG. It trades about 0.24 of its potential returns per unit of risk. Crispr Therapeutics AG is currently generating about 0.09 per unit of risk. If you would invest 2,771 in Apellis Pharmaceuticals on August 31, 2024 and sell it today you would earn a total of 643.00 from holding Apellis Pharmaceuticals or generate 23.2% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Apellis Pharmaceuticals vs. Crispr Therapeutics AG
Performance |
| Timeline |
| Apellis Pharmaceuticals |
| Crispr Therapeutics |
Apellis Pharmaceuticals and Crispr Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Apellis Pharmaceuticals and Crispr Therapeutics
The main advantage of trading using opposite Apellis Pharmaceuticals and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Apellis Pharmaceuticals position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.| Apellis Pharmaceuticals vs. Cue Biopharma | Apellis Pharmaceuticals vs. Tff Pharmaceuticals | Apellis Pharmaceuticals vs. Eliem Therapeutics | Apellis Pharmaceuticals vs. Inhibrx |
| Crispr Therapeutics vs. Beam Therapeutics | Crispr Therapeutics vs. Editas Medicine | Crispr Therapeutics vs. Caribou Biosciences | Crispr Therapeutics vs. Verve Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Complementary Tools
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |